Alivus Life Sciences Gears Up for Q3 Reveal on 22nd January; Check Key Expectations Here

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Wed Jan 21 2026

Alivus Life Sciences Gears Up for Q3 Reveal on 22nd January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results

Alivus Life Sciences Q3 FY26 results are scheduled to be announced on 22nd January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Alivus Life Sciences Q3 Results 2026 Preview

Alivus Life Sciences’ revenue is expected to be in the range of ₹641.84 crore, up 26.63% YoY.
Profit After Tax, or PAT, is projected to rise by 43.69% YoY.
Alivus Life Sciences’ EBITDA is expected to rise to ₹175.15 crore.
Net profit is ₹136.96 crore, up 43.69% YoY

Alivus Life Sciences Share Performance

Over the past six months, Alivus Life Sciences’ share price has fallen by 18.28% to ₹862.90.
Moreover, over the past year, the stock has decreased by 24.96%.
Despite this weak short-term performance, Alivus Life Sciences’ stock has delivered a financially sound 24.92% return over the past 5 years.
As of 21st January 2026, the stock traded at ₹862.90 per share.

Key Factors to Watch for Alivus Life Sciences

API Portfolio Expansion & Complex Molecules: Growth in high-value APIs and high-potency APIs (HPAPIs) boosts margins and enhances competitive differentiation.
Capacity & CDMO Scale-Up: Progress in capacity expansions (Solapur, Ankleshwar, Dahej) and ramp-up of CDMO projects supports long-term revenue and utilisation.
Geographic & Market Diversification: A broad presence in regulated markets (North America, Europe, Japan, LATAM) and a diversified customer base reduces reliance on any single region or client.
Operational Efficiency & Financial Strength: Strong margins, healthy cash position, net-debt-free balance sheet, and disciplined cost control help sustain profitability amid pricing and raw-material pressures.

Final Thoughts

Alivus Life Sciences will announce its Q3 FY26 results on 22nd January 2026. Analysts expect 13.80% YoY revenue growth, a 303.22% rise in PAT, and a 223.80% rise in EBITDA. Alivus Life Sciences focuses on developing, manufacturing, and supplying high-quality active pharmaceutical ingredients (APIs) and CDMO services for global pharmaceutical partners.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!